RBCNPs modified with transferrin receptor aptamer (TfR-A) were employed for brain-targeted CD22 shRNA plasmid delivery, inhibiting abnormal CD22 expression in aging microglia and enhancing Aβ phagocytosis in AD mouse brain tissue [35]. Here, CD22 is linked to Alzheimer disease.